Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” ...

Thermo Fisher was the pandemic powerhouse, with its products well-aligned to meet the skyrocketing demand for diagnostics and vaccine research. The stock price witnessed a surge during COVID-19.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twenty-two brokerages that are currently covering the stock, ...